CN1819824A - 抗氧化剂在皮肤病和/或化妆品组合物中的用途 - Google Patents
抗氧化剂在皮肤病和/或化妆品组合物中的用途 Download PDFInfo
- Publication number
- CN1819824A CN1819824A CNA2004800191677A CN200480019167A CN1819824A CN 1819824 A CN1819824 A CN 1819824A CN A2004800191677 A CNA2004800191677 A CN A2004800191677A CN 200480019167 A CN200480019167 A CN 200480019167A CN 1819824 A CN1819824 A CN 1819824A
- Authority
- CN
- China
- Prior art keywords
- antioxidant
- acne
- compositions
- dermatosis
- active principle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 35
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 33
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 206010000496 acne Diseases 0.000 claims abstract description 39
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 36
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 34
- 208000017520 skin disease Diseases 0.000 claims abstract description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
- 229930195725 Mannitol Natural products 0.000 claims abstract description 10
- 239000000594 mannitol Substances 0.000 claims abstract description 10
- 235000010355 mannitol Nutrition 0.000 claims abstract description 10
- GHPVDCPCKSNJDR-UHFFFAOYSA-N 2-hydroxydecanoic acid Chemical compound CCCCCCCCC(O)C(O)=O GHPVDCPCKSNJDR-UHFFFAOYSA-N 0.000 claims abstract description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003935 flavonoid Natural products 0.000 claims abstract description 7
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 7
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 7
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 7
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000005493 rutin Nutrition 0.000 claims abstract description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 5
- 229960004555 rutoside Drugs 0.000 claims abstract description 5
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 5
- 239000011718 vitamin C Substances 0.000 claims abstract description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- LMHJFKYQYDSOQO-UHFFFAOYSA-N hydroxydecanoic acid Natural products CCCCCC(O)CCCC(O)=O LMHJFKYQYDSOQO-UHFFFAOYSA-N 0.000 claims abstract description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000005875 quercetin Nutrition 0.000 claims abstract description 4
- 229960001285 quercetin Drugs 0.000 claims abstract description 4
- 210000002374 sebum Anatomy 0.000 claims description 22
- -1 gallic acid ester Chemical class 0.000 claims description 15
- 206010048768 Dermatosis Diseases 0.000 claims description 14
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical group CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 7
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000004761 scalp Anatomy 0.000 claims description 5
- PJPKKWPXVRGUEO-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;nonanedioic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)CCCCCCCC(O)=O PJPKKWPXVRGUEO-ZSCHJXSPSA-N 0.000 claims description 4
- 229940074391 gallic acid Drugs 0.000 claims description 4
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- 239000000473 propyl gallate Substances 0.000 claims description 4
- 229940075579 propyl gallate Drugs 0.000 claims description 4
- 235000010388 propyl gallate Nutrition 0.000 claims description 4
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- SBLKVIQSIHEQOF-UPHRSURJSA-N Octadec-9-ene-1,18-dioic-acid Chemical compound OC(=O)CCCCCCC\C=C/CCCCCCCC(O)=O SBLKVIQSIHEQOF-UPHRSURJSA-N 0.000 abstract 1
- 229940067597 azelate Drugs 0.000 abstract 1
- 235000018977 lysine Nutrition 0.000 abstract 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 abstract 1
- 229940116918 octadecenedioic acid Drugs 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 8
- 235000013599 spices Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- 235000011201 Ginkgo Nutrition 0.000 description 4
- 244000194101 Ginkgo biloba Species 0.000 description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010039792 Seborrhoea Diseases 0.000 description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 229940031439 squalene Drugs 0.000 description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241001464975 Cutibacterium granulosum Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种用于治疗痤疮、脂溢性皮炎和与粉刺形成相关的皮肤疾病的皮肤病和/或化妆品组合物。本发明的特征是，它含有：选自棓酸酯、类黄酮、丁基化羟基甲苯(BHT)、丁基羟基苯甲醚(BHA)、十八烯二酸和羟基癸酸的至少一种亲脂性抗氧化剂作为其活性要素；以及至少一种第二活性要素，其形式为选自甘露醇、维生素C、壬二酸赖氨酸、芸香苷和槲皮素的亲水性抗氧化剂。
Description
本发明涉及痤疮和与粉刺形成相关的皮肤疾病的治疗。
粉刺是寻常痤疮的主要损伤，该损伤由毛囊管壁的细胞阻塞，阻止皮脂细胞(皮脂腺的细胞)生产的皮脂到达皮肤表面引起。皮脂和细胞的混合物形成栓塞，称为粉刺，在如此栓塞的毛孔中造成通常靠皮肤生活的细菌，如痤疮丙酸杆菌(Propionibacterium acnes)和颗粒丙酸杆菌(Propionibacterium granulosum)以及酵母，具体是皮屑芽孢菌(Malassezia furfur)的繁殖。这些细菌具有不同的代谢皮脂甘油三酯和释放脂肪酸的特征，这引起组织发炎。
由此引起的脂溢性皮炎反映为长出红斑或疙瘩，覆有淡黄色油性鳞屑，或多或少地发痒，主要发生在富含皮脂腺的区域。在面部，该损伤的区域分布是提示性的：鼻子和嘴唇之间的沟、眉毛根、头皮、鼻翼、耳廓褶、耳甲、外耳道。在头皮上，或多或少的脂溢性头屑症状反映了它常常发作。在躯干上，在男性中注意到两处频发区域：胸骨和两块肩胛骨之间的区域。
皮脂是富含脂肪酸，和尤其是角鲨烯、含有30个碳原子的脂肪烃即胆固醇前体的油脂分泌的产物。皮脂，尤其在保护皮肤方面起到重要的积极作用，但自1969年以来，人们确定，在皮脂分泌水平和痤疮的严重程度之间存在关联(Cunliffe，W.J.等，Lancet，I，685，1969，The Pathogenesis of Acne)。
因此，在现代化妆业和皮肤学中，在为减少和控制皮脂腺过度分泌，尤其是为减少难看的后果，如皮肤和头皮的油脂性外观，而且也为降低粉刺的形成和产生的发炎而开发组合物方面进行了很多研究。
由于去除了皮脂，使它们不能再起到保护性作用，所以这些组合物具有明显副作用，如皮肤干燥、紧绷感、甚至发炎。
关于治疗毛发，将提及FR 2 099 582中揭示的毛发组合物，它在溶液中至少包括一种酚衍生物，所述组合物用于使毛发脱臭，但除此脱臭作用之外，它还减慢皮脂分泌，施用它似乎具有强烈减慢分泌或改善较低流动性的效果。
近年来的科学研究显示，皮脂的一种组分，角鲨烯尤其是角鲨烯的氧化产物具有粉刺发生性和刺激性(Saint-Léger等，British J.of Dermatology，114，543-552，1986；Chiba K.等，The J.of Toxicological Sciences，25，77-83，2000和Uchino.T.等，Biol.Pharm.Bulletin，25(5)，605-610，2002)。
更具体说，已确定，患痤疮的病人的皮脂组合物高度富含角鲨烯。
本申请公司也指出，构成皮脂的脂类物质的氧化导致所述皮脂的粘度增加，并增加粉刺形成，流动性较低的皮脂不再可能从毛囊管流出，该氧化可能由细菌组分和紫外线辐射引起，导致形成使皮脂变稠和高度致粉刺发生的粘稠聚合物。
因此，本发明涉及通过阻止皮脂变稠来提高皮脂质量从而降低对角质细胞增殖的诱导，导致降低粉刺发生的组合物。
令人惊讶的是，在没有改变皮脂流动，即没有影响所产生皮脂量的情况下，而通过降低粉刺发生性、通过校正其质量和通过防止其变稠得到关于患有痤疮的皮肤的结果。
本发明更具体地涉及使维持皮脂流动性成为可能的组合物，更具体涉及用于治疗痤疮、脂溢性皮炎和与粉刺形成相关的皮肤疾病的皮肤病和/或化妆品用途的组合物，其特征是它包含选自棓酸酯、类黄酮、丁基化羟基甲苯(BHT)、丁基化羟基苯甲醚(BHA)、十八烯二酸和羟基癸酸的至少一种亲脂性抗氧化剂作为其活性要素。
也涉及如上所述的组合物，其特征是它还包含至少一种第二活性要素、选自甘露醇、维生素C、壬二酸赖氨酸、芸香苷和槲皮素的亲水性抗氧化剂。
本发明也涉及其中亲脂性抗氧化剂是棓酸十二烷酯的组合物。
本发明也涉及其中亲脂性抗氧化剂是棓酸丙酯的组合物。
本发明也涉及其中亲脂性抗氧化剂是棓酸辛酯的组合物。
类黄酮可以，例如，由植物萃取物如白果或绿茶萃取物提供。
活性要素的量，即亲水性或亲脂性抗氧化剂的量或两种抗氧化剂的总量在组合物重量的0.0001和20％之间，优选在组合物重量的0.0001和10％之间。
上述量优选在组合物重量的0.001和2％之间。
本发明也涉及使皮脂流动的方法，其特征是它包括将上述的本发明组合物施用于皮肤或头皮。
在药学上可接受的介质中，该组合物包含至少一种活性要素，即一种亲脂性抗氧化剂。
药学上可接受的介质，即剂型环境，必须是既不可氧化也不具氧化性，即所用赋形剂在施用于皮肤的条件下必须是不可氧化且稳定的，并且必须不引起氧化反应。
因此，本发明涉及如上所述的组合物，其特征是它不含在使用条件下能够氧化的赋形剂。
本发明组合物可任选地含有各种不可氧化的添加剂，如悬浮剂，乳化剂，阴离子、阳离子、非离子性或两性聚合物，蛋白质，维生素，表面活性剂，矿物或植物油，硅氧烷蜡，树胶和/或树脂，增稠剂，酸化或碱化剂，溶剂，pH稳定剂，UV稳定剂，防腐剂，抗菌剂和抗真菌剂，香料或化妆品中或皮肤病学中常用的其它佐剂。
优选地，以适合通过局部皮肤途径给药的形式和覆盖所有化妆品或皮肤病学的形式提供本发明组合物。这些组合物含有化妆品中和/或皮肤病学上可接受的介质，即与皮肤或毛发，包括头发相容的介质。这些组合物具体可以呈适合施用于皮肤、嘴唇和/或毛发的乳膏，O/W、W/O乳剂或多相乳剂，溶液，悬液，凝胶，乳液、洗剂、粘着剂或粉剂的形式。
本发明也涉及在用于治疗痤疮和/或由粉刺形成引起的皮肤疾病的皮肤病和/或化妆品组合物的制备中至少一种亲脂性抗氧化剂的用途。
更具体地涉及如上所述的用途，其特征是该亲脂性抗氧化剂选自棓酸酯和类黄酮。
在另一形式中，该亲脂性抗氧化剂选自丁基化羟基甲苯(BHT)、丁基化羟基苯甲醚(BHA)、十八烯二酸和羟基癸酸。
本发明也涉及当亲脂性抗氧化剂是棓酸十二烷酯时的所述用途。
本发明也涉及当亲脂性抗氧化剂是棓酸丙酯时的所述用途。
本发明也涉及当亲脂性抗氧化剂是棓酸辛酯时的所述用途。
类黄酮可以，例如，由植物萃取物如白果或绿茶萃取物提供。
本发明也涉及在用于治疗痤疮和/或由粉刺形成引起的皮肤疾病的皮肤病和/或化妆品组合物的制备中亲水性抗氧化剂与亲脂性抗氧化剂结合的用途。
也涉及如上所述的用途，其特征是亲水性抗氧化剂选自甘露醇和维生素C。
在另一形式中，该亲水性抗氧化剂选自壬二酸赖氨酸、芸香苷和槲皮素。
根据本发明，所用亲水性或亲脂性抗氧化剂的量或两种抗氧化剂的总量在组合物重量的0.0001和20％之间，优选在组合物重量的0.0001和10％之间。
上述量优选在组合物重量的0.001和2％之间。
阅读以例子方式给出并且不包含限制意思的实施例后，本发明的其它优点和特征将变得更加显而易见。
实施例1-制备活性混合物
Sepigel 305(聚丙烯酰胺和C13-14异链烷烃和月桂基聚氧乙烯(7)醚) 2％
棓酸十二烷酯 0.0001％
甘露醇 0.50％
防腐剂(对羟基苯甲酸酯类) 0.20％
EDTA(螯合剂) 0.10％
水 足量至100％
实施例2-本发明组合物的效果
在一组约30位志愿者中测试了含有棓酸十二烷酯、甘露醇和白果萃取物作为活性要素的本发明组合物。
试验对象平均年龄为23岁(18-34岁)，具有中度多形青春痘，即平均具有约40个保留性或炎性损伤。
在除鼻锥体的整个面部仅观察计数保留性损伤，即小囊和粉刺。
将本发明组合物施用于面部，每天两次，共8周。
施用8周后，记录显示至少40％对象的保留性损伤减少，20％对象显示出小囊减少50-90％，15％对象显示出粉刺减少50-90％，10％对象粉刺完全消失。
实施例3-制备组合物
通过简单地混合各种组分获得这些组合物。所示量以重量百分数表示。
水包油乳剂
Montanov 68(十六/十八醇和十六/十八烷基葡糖苷(Cetearyl glucoside)) 5.00％
霍霍巴油 5.00％
BHT 0.05％
棕榈酸异丙酯 7.00％
甘油 5.00％
尿囊素 0.10％
甘露醇v 3.00％
Sepigel 305(聚丙烯酰胺和C13-14异链烷烃和月桂基聚氧乙烯(7)醚) 0.30％
Phenonip 0.50％
香料 0.50％
水 足量至100％
凝胶
Carbopol Ultrez 10(溶液，2％) 25％
三乙醇胺 0.50％
甘露醇 2.00％
棓酸十二烷酯 0.0001％
防腐剂 0.20％
EDTA(螯合剂) 0.10％
香料 0.50％
水 足量至100％
洗剂
单丙二醇 1.00％
尿囊素 0.30％
甘油 1.00％
Cetiol HE(聚氧乙烯(7)甘油醚椰油酸酯) 1.00％
壬二酸赖氨酸 5.00％
BHA 0.01％
防腐剂 0.20％
香料 0.50％
水 足量至100％
用于脂溢性油性皮肤的发泡凝胶
化合物(90％甘露醇和10％棕榈酸抗坏血酸酯) 2.00％
香料 0.30％
氯化钠 1.00％
57％乙醇酸的水溶液 0.50％
氧乙烯化(60EO)氢化牛油醇和十四烷二醇的共聚物 0.90％
甘油 3.00％
38％氨基乙酸N-二钠N-羧基乙氧基乙基-N-(椰油基酰氨基乙基)酯的水溶液 5.00％
28％月桂醚硫酸钠(C12-14 70/30)(2.2EO)的水溶液 14.30％
椰油脂肪酸二乙醇酰胺 0.70％
氧乙烯化(26EO)/氧丙烯化(26PO)丁醇、
氧乙烯化(40EO)氢化蓖麻油的混合物水溶液 1.00％
软化水 足量至100％
用于脂溢性皮肤的治疗性凝胶
棕榈酸抗坏血酸酯 1.00％
香料 0.20％
黄原胶 1.00％
甘油 2.00％
乙醇 20.00％
芸香苷 0.10％
氧乙烯化(26EO)/氧丙烯化(26PO)丁醇、
氧乙烯化(40EO)氢化蓖麻油的混合物水溶液 1.00％
软化水 足量至100％
用于患有痤疮的皮肤和头屑症状的纯化洗剂
BHA 0.05％
棓酸丙酯 0.0005％
香料 0.20％
乙醇 20.00％
甘油 2.00％
氧乙烯化(26EO)/氧丙烯化(26PO)丁醇、
氧乙烯化(40EO)氢化蓖麻油的混合物水溶液 1.00％
Octopirox 0.20％
软化水 足量至100％
为了补充本发明组合物的作用并增加其有效性和耐受性，可以将其它活性要素与抗氧化剂结合。
这导致，该作用的各组分使组合物可能满足有痤疮倾向的皮肤的复杂要求。
本发明组合物还可包含具有角质层分离活性的选自α-羟酸和/或水杨酸的酯的活性要素，该要素使得清除和防止形成也可促进粉刺形成的角质细胞团成为可能。
它们还可包含锌盐，例如葡糖酸锌，它由于对5α-还原酶的抑制作用而具有皮脂分泌调节作用，而且在高浓度时，具有对痤疮丙酸杆菌的杀菌作用，而粉刺中这种细菌的繁殖是痤疮的特有的。
向本发明组合物中加入高浓度的含锌活性要素使得在局部或全身施用中补充抗生素治疗，如红霉素治疗的作用成为可能。
本发明组合物也可含有消炎或润肤活性要素，如18β-甘草亭酸(甘草次酸)，其内源性消炎作用是由于它抑制了造成将皮质醇转化成可的松的酶，或者描述为炎症级联反应抑制剂的白果萃取物。
通过剂型基料含有因其增湿性选出的甘油和木糖醇来补充这些活性要素的作用。
Claims (12)
1.一种用于治疗痤疮、脂溢性皮炎和与粉刺形成有关的皮肤疾病的皮肤病和/或化妆品用途的组合物，其特征在于，它包含选自棓酸酯、类黄酮、丁基化羟基甲苯(BHT)、丁基化羟基苯甲醚(BHA)、十八烯二酸和羟基癸酸的至少一种亲脂性抗氧化剂作为其活性要素，以及至少一种第二活性要素，选自甘露醇、维生素C、壬二酸赖氨酸、芸香苷和槲皮素的亲水性抗氧化剂。
2.如权利要求1所述的组合物，其特征在于，所述亲脂性抗氧化剂是棓酸十二烷酯。
3.如权利要求1所述的组合物，其特征在于，所述抗氧化剂是棓酸丙酯。
4.如权利要求1所述的组合物，其特征在于，所述抗氧化剂是棓酸辛酯。
5.如上述权利要求中任一项所述的组合物，其特征在于，所述活性要素的量在组合物重量的0.0001和20％之间，优选在组合物重量的0.0001和10％之间。
6.如权利要求1或2所述的组合物，其特征在于，所述活性要素的量在组合物重量的0.001和2％之间。
7.如上述权利要求中任一项所述的组合物，其特征在于，所述组合物不含在使用条件下能够氧化的赋形剂。
8.亲脂性抗氧化剂在制备用于治疗痤疮和/或由于粉刺形成引起的皮肤疾病的皮肤病和/或化妆品组合物中的应用。
9.亲水性抗氧化剂与亲脂性抗氧化剂组合在制备用于治疗痤疮和/或由于粉刺形成引起的皮肤疾病的皮肤病和/或化妆品组合物中的应用。
10.如权利要求9或10所述的应用，其特征在于，所述亲脂性抗氧化剂选自棓酸酯和类黄酮。
11.如权利要求10所述的用途，其特征在于，所述亲水性抗氧化剂选自甘露醇和维生素C。
12.一种使皮脂流动的方法，其特征在于，所述方法包括将权利要求1-8中任一项所述的组合物施用于皮肤或头皮。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0308288A FR2857266B1 (fr) | 2003-07-07 | 2003-07-07 | Composition a usage dermatologique et/ou cosmetique, comprenant a titre de principe actif au moins un antioxydant lipophile |
| FR03/08288 | 2003-07-07 | ||
| PCT/FR2004/001768 WO2005004891A2 (fr) | 2003-07-07 | 2004-07-07 | Utilisation d’un antioxydant dans une composition a usage dermatologique et/ou cosmetique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1819824A true CN1819824A (zh) | 2006-08-16 |
| CN1819824B CN1819824B (zh) | 2010-05-12 |
Family
ID=33522825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800191677A Expired - Lifetime CN1819824B (zh) | 2003-07-07 | 2004-07-07 | 抗氧化剂在皮肤病和/或化妆品组合物中的用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060159714A1 (zh) |
| EP (1) | EP1641476B1 (zh) |
| JP (1) | JP2007516185A (zh) |
| KR (1) | KR101161682B1 (zh) |
| CN (1) | CN1819824B (zh) |
| CA (1) | CA2531186C (zh) |
| ES (1) | ES2622402T3 (zh) |
| FR (1) | FR2857266B1 (zh) |
| WO (1) | WO2005004891A2 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818934A (zh) * | 2018-02-28 | 2020-10-23 | 西姆莱斯股份公司 | 皮肤病产品 |
| CN115820338A (zh) * | 2023-02-22 | 2023-03-21 | 中国科学院昆明植物研究所 | 一种脱臭青刺果油的制备方法及其应用 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005031482A1 (de) * | 2005-07-04 | 2007-01-18 | Henkel Kgaa | Hautaufhellende Zusammensetzungen mit verbesserter Wirkung |
| US20070185038A1 (en) * | 2005-09-30 | 2007-08-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin care actives |
| WO2010080543A1 (en) * | 2008-12-18 | 2010-07-15 | Guthery B Eugene | Acne vulgaris treatment regimen |
| US20100233301A1 (en) | 2009-03-11 | 2010-09-16 | Jing Cheng | Topical compositions comprising fermented extracts of traditional chinese medicinal (tcm) ingredients, and methods of making and using same |
| US20100260695A1 (en) * | 2009-04-09 | 2010-10-14 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
| FR2981275B1 (fr) | 2011-10-18 | 2015-03-20 | Jean Noel Thorel | Composition a base de meroterpene destinee aux peaux grasses, a tendance acneique ou atteintes d'acne |
| CN103655416B (zh) * | 2013-11-26 | 2015-05-06 | 郑州高尚生物科技有限公司 | 一种多效祛痘美容霜及其制备方法 |
| KR101602468B1 (ko) * | 2014-01-17 | 2016-03-10 | 주식회사 엘지생활건강 | 하이드록시 데카노익애씨드를 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물 |
| FR3024037B1 (fr) | 2014-07-25 | 2018-03-02 | Sederma | Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques |
| JP6907348B2 (ja) * | 2015-06-12 | 2021-07-21 | ロート製薬株式会社 | アクネ菌バイオフィルム破壊組成物 |
| JP2017001993A (ja) * | 2015-06-12 | 2017-01-05 | ロート製薬株式会社 | アクネ菌バイオフィルム破壊組成物 |
| FR3042710B1 (fr) | 2015-10-22 | 2019-12-13 | Jean-Noel Thorel | Composition a base de dihydromyricetine et d'un sel de zinc pour le traitement de l'acne et des peaux grasses |
| KR102023021B1 (ko) * | 2016-02-25 | 2019-09-19 | 주식회사 엘지생활건강 | 하이드록시 데카노익애씨드를 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물 |
| FR3073741B1 (fr) | 2017-11-20 | 2019-10-18 | Jean-Noel Thorel | Composition cosmetique stabilisante pour reduire la degradation d'actifs cosmetiques instables |
| JP7134745B2 (ja) * | 2018-06-29 | 2022-09-12 | サンスター株式会社 | 乳化組成物 |
| WO2020172455A1 (en) * | 2019-02-20 | 2020-08-27 | Rodan & Fields, Llc | Synergistic antioxidant compositions |
| JP7166397B2 (ja) * | 2020-01-07 | 2022-11-07 | ロート製薬株式会社 | アクネ菌バイオフィルム破壊組成物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3984535A (en) * | 1970-07-24 | 1976-10-05 | L'oreal | Scalp deodorant composition |
| LU61405A1 (zh) * | 1970-07-24 | 1972-02-10 | ||
| IN142640B (zh) * | 1975-01-17 | 1977-08-06 | Johnson & Johnson | |
| JPS5944313A (ja) * | 1982-09-07 | 1984-03-12 | Yakult Honsha Co Ltd | 抗菌性組成物 |
| JPS6284021A (ja) * | 1985-10-08 | 1987-04-17 | Shiseido Co Ltd | テストステロン−５α−レダクタ−ゼ阻害剤 |
| DE3738405A1 (de) * | 1987-11-12 | 1989-05-24 | Henkel Kgaa | Sebosuppressive zubereitungen |
| FI903483A0 (fi) * | 1989-07-13 | 1990-07-10 | Bristol Myers Squibb Co | Tretinoin innehaollande stabila emulsionskraemformulationer. |
| US5559149A (en) * | 1990-01-29 | 1996-09-24 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions containing retinoids |
| FR2694934B1 (fr) * | 1992-08-24 | 1994-11-10 | Oreal | Composition pour le traitement de l'acné contenant un dérivé d'acide salicylique et dérivés d'acide salicylique. |
| CN1077354A (zh) * | 1992-12-16 | 1993-10-20 | 石道元 | 心脑血管保健食品添加剂及其制备方法 |
| DE4328871A1 (de) * | 1993-08-27 | 1995-03-02 | Beiersdorf Ag | Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis |
| FR2717079B1 (fr) * | 1994-03-11 | 1996-04-12 | Oreal | Composition contenant un oxyde de métal non photocatalytique et du tocophérol, son utilisation dans le domaine cosmétique et/ou dermatologique et procédés la mettant en Óoeuvre. |
| JPH08283150A (ja) * | 1995-04-12 | 1996-10-29 | Kao Corp | 抗炎症剤 |
| JP3560424B2 (ja) * | 1996-08-30 | 2004-09-02 | 株式会社ノエビア | 抗菌性組成物 |
| US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| US6576660B1 (en) * | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
| CN1186690A (zh) * | 1998-01-11 | 1998-07-08 | 胡茂德 | 银杏痤疮膏处方及其用途 |
| WO1999059580A1 (fr) * | 1998-05-15 | 1999-11-25 | Showa Denko K.K. | Agents preventifs/therapeutiques pour les affections cutanees |
| US6495126B1 (en) * | 1999-07-20 | 2002-12-17 | Mary Kay Inc. | Treatment and composition for achieving skin anti-aging benefits by corneum protease activation |
| GB9921238D0 (en) * | 1999-09-09 | 1999-11-10 | Boots Co Plc | Skincare composition |
| JP2001181173A (ja) * | 1999-12-27 | 2001-07-03 | Kose Corp | 美白外用剤 |
| US6438002B2 (en) * | 2000-02-02 | 2002-08-20 | General Electric Co. | Active snubber circuit with controllable DV/DT |
| US6531141B1 (en) * | 2000-03-07 | 2003-03-11 | Ortho-Mcneil Pharmaceutical, Inc. | Oil-in-water emulsion containing tretinoin |
| JP4070935B2 (ja) * | 2000-03-31 | 2008-04-02 | 株式会社コーセー | にきび用皮膚外用剤 |
| FR2807322B1 (fr) * | 2000-04-10 | 2004-02-20 | Oreal | Composition, notamment cosmetique, comprenant de l'acide ascorbique en association avec un derive d'acide ascorbique |
| DE10034328A1 (de) * | 2000-07-14 | 2002-01-31 | Fribad Cosmetics Gmbh | Kosmetisches Mittel zur äußeren Anwendung auf der Haut und deren Verwendung |
| AU2001277786A1 (en) * | 2000-08-04 | 2002-02-18 | Angiolab, Inc. | Composition containing ginkgo biloba that inhibit angiogenesis and matrix metalloproteinase |
| JP2002284626A (ja) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | 皮膚外用剤 |
| JP2003026560A (ja) * | 2001-07-12 | 2003-01-29 | Kanebo Ltd | 活性酸素消去剤、老化防止用皮膚化粧料、及び活性酸素消去能の安定化方法。 |
| JP2003081850A (ja) * | 2001-09-14 | 2003-03-19 | Maruzen Pharmaceut Co Ltd | 皮膚化粧料 |
| JP2003306446A (ja) * | 2002-02-14 | 2003-10-28 | Fancl Corp | 皮膚老化防止剤及び／又はニキビ改善剤キット |
| JP2004010505A (ja) * | 2002-06-04 | 2004-01-15 | Fancl Corp | 化粧料 |
-
2003
- 2003-07-07 FR FR0308288A patent/FR2857266B1/fr not_active Expired - Lifetime
-
2004
- 2004-07-07 CN CN2004800191677A patent/CN1819824B/zh not_active Expired - Lifetime
- 2004-07-07 EP EP04767603.6A patent/EP1641476B1/fr not_active Expired - Lifetime
- 2004-07-07 KR KR1020067000439A patent/KR101161682B1/ko active IP Right Grant
- 2004-07-07 JP JP2006518291A patent/JP2007516185A/ja active Pending
- 2004-07-07 US US10/562,443 patent/US20060159714A1/en not_active Abandoned
- 2004-07-07 WO PCT/FR2004/001768 patent/WO2005004891A2/fr active Application Filing
- 2004-07-07 ES ES04767603.6T patent/ES2622402T3/es not_active Expired - Lifetime
- 2004-07-07 CA CA2531186A patent/CA2531186C/fr not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818934A (zh) * | 2018-02-28 | 2020-10-23 | 西姆莱斯股份公司 | 皮肤病产品 |
| US11786570B2 (en) | 2018-02-28 | 2023-10-17 | Symrise Ag | Dermatological product |
| CN115820338A (zh) * | 2023-02-22 | 2023-03-21 | 中国科学院昆明植物研究所 | 一种脱臭青刺果油的制备方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2531186C (fr) | 2013-04-09 |
| FR2857266B1 (fr) | 2007-09-21 |
| CN1819824B (zh) | 2010-05-12 |
| EP1641476A2 (fr) | 2006-04-05 |
| US20060159714A1 (en) | 2006-07-20 |
| KR20060028744A (ko) | 2006-03-31 |
| WO2005004891A3 (fr) | 2005-06-09 |
| FR2857266A1 (fr) | 2005-01-14 |
| CA2531186A1 (fr) | 2005-01-20 |
| ES2622402T3 (es) | 2017-07-06 |
| EP1641476B1 (fr) | 2017-03-29 |
| WO2005004891A2 (fr) | 2005-01-20 |
| KR101161682B1 (ko) | 2012-07-02 |
| JP2007516185A (ja) | 2007-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1819824A (zh) | 抗氧化剂在皮肤病和/或化妆品组合物中的用途 | |
| KR101420599B1 (ko) | 항여드름제를 함유하는 조성물 및 이의 용도 | |
| JP2020529980A (ja) | 皮膚の弛緩と身体の輪郭を改善するための組成物および方法 | |
| ES2565317T3 (es) | Composición tópica para el cuidado de la piel | |
| CN1300215A (zh) | 皮肤病防治剂 | |
| US20200222358A1 (en) | Topical dermatologic acne treatment cream composition and method of manufacture | |
| CN1109740A (zh) | 用有效量的活性物质来治疗混合皮肤 | |
| KR20110036683A (ko) | 피부 치료용 벤조일 퍼옥사이드 조성물 | |
| KR101445182B1 (ko) | 국소용 팔미토일 글루타치온 제제 | |
| CN1279901C (zh) | 用于治疗皮脂溢的含有取代的氧杂螺[2,5]辛烷的衍生物的药物组合物 | |
| CN109498478A (zh) | 一种富勒烯外用组合物 | |
| KR101530307B1 (ko) | 국소용 아실 글루타치온 제제 | |
| CN1795926A (zh) | 治疗皮肤症状的方法 | |
| JP2003128531A (ja) | 皮膚外用剤 | |
| JPH1179930A (ja) | 皮膚用アスコルビン酸誘導体組成物 | |
| KR20110138709A (ko) | 5-아미노레불린산 또는 이의 에스테르를 포함하는 여드름 개선용 조성물 | |
| CN113520893A (zh) | 一种去角质组合物及去角质凝露 | |
| CN1809330A (zh) | 含有植烷酸或其衍生物的局部用制剂 | |
| JP6222894B2 (ja) | 表皮肥厚促進剤 | |
| WO2023068233A1 (ja) | 活性阻害及び／又は産生抑制剤 | |
| FR2897534A1 (fr) | Utilisation du tesaglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques | |
| JP2001322932A (ja) | 活性酸素消去剤及びこれを含有してなる活性酸素消去用の組成物 | |
| CN1720020A (zh) | 黑素细胞的树突伸长抑制剂以及含有该抑制剂的皮肤外用剂 | |
| CN1568978A (zh) | 用于预防或治疗青春痘的组合物 | |
| JP2005187422A (ja) | 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20100512 |
|
| CX01 | Expiry of patent term |